{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Enpoints', 'baseline)', 'Change from baseline in COPD', 'assessment test (CAT)', 'Percentage of responders according to', 'CAT (defined as a >2 unit improvement', 'in score from baseline)', 'Other', 'To compare UMEC/VI (62.5/25 mcg', 'Rate of mild, moderate or', 'severe', 'once daily), UMEC (62.5 mcg once', 'exacerbations', 'daily) with salmeterol (50 mcg twice', 'daily) on other COPD efficacy measures', 'Time to first mild, moderate or severe', 'exacerbation', 'Rate of moderate or severe', 'exacerbation', 'Time to moderate or severe', 'exacerbation', 'Time to severe exacerbations', 'Time to clinically important', 'deterioration (CID) composite endpoint', 'Time to clinically important', 'deterioration composite endpoint', 'excluding FEV1', 'Rescue albuterol/salbutamol use,', '(percentage of rescue-free days and', 'mean number of Inhalations/day)', 'captured by the electronic diary', '(eDiary) over 24 weeks', 'Inspiratory capacity (IC)', 'Full Vital capacity (FVC)', 'Change from baseline in trough FEV1', 'Change from baseline in global', 'impression of disease severity', '11']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Enpoints', 'Safety', 'To evaluate safety and tolerability', 'Incidence of adverse events', 'of UMEC/VI (62.5/25 mcg once', 'daily), UMEC (62.5mcg once daily)', 'and salmeterol 50mcg twice daily)', 'Exploratory', 'To compare albuterol/salbutamol', 'Rescue albuterol/salbutamol use,', 'use captured in the eDiary with the', '(percentage of rescue-free days and', 'electronic metered dose inhaler', 'mean number of Inhalations/day)', '(eMDI) device', 'captured by the eMDI device over 24', 'weeks as data allow', 'To explore the effect of UMEC/VI', 'Change from baseline in physical', '(62.5/25 mcg once daily), UMEC', 'activity', '(62.5 mcg once daily) with', 'salmeterol (50 mcg twice daily) on', 'physical activity', 'To investigate the CID composite', 'To compare physical activity levels,', 'endpoint ability to predict short', 'ER-S, rescue medication use,', 'term outcomes', 'exacerbations and mortality in subjects', 'with and without a CID', 'Overall Design', 'This is a multi-centre, randomized, double blind, double dummy, 3-arm parallel group', 'study. Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation', 'powder (62.5/25 mcg once daily) administered via the ELLIPTA dry powder inhaler', 'R', '(DPI), or UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI or salmeterol', '(50 mcg twice daily (BID)) administered via the DISKUSR DPI.', 'Eligible subjects at Screening will enter a run-in period for 4 weeks during which they', 'continue taking their inhaled COPD medications (excluding ICS and any exclusionary', 'medications). In addition, subjects will be provided with short acting', 'albuterol/salbutamol to be used on as needed basis (rescue medication) throughout the', 'study.', 'Subjects who experience a moderate or severe COPD exacerbation during the run-in', 'period will be deemed run-in failures. Subjects experiencing a mild exacerbation,', 'defined as worsening of symptoms that requires no treatment with antibiotics or steroids', 'and is self managed by the patient by an increase of inhaled rescue medication, will be', 'allowed to continue in the study.', 'At the randomization Visit 2 (Day 1) those subjects who successfully complete the run-in', 'period as well as meet the other pre-defined eligibility and randomization criteria will', 'discontinue their inhaled COPD medications and will be randomized to one of the 3', 'treatment arms for 24 weeks.', '12']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'All subjects will be given an eDiary for use during the run-in, and treatment period to', 'complete PRO questionnaires and record medical problems experienced during the study.', 'Subjects will be performing slow and forced spirometry at specific visits.', 'In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of', 'their physical activity measured through a physical activity monitor (Actigraph GT9X)', 'worn for 7 days from Screening (Visit 1), for 7 days from Randomisation (Visit 2), 7', 'days from Visit 3, and for 7 days prior to last clinic Visit (Visit 5).', 'There will be a total of 5 clinic visits and one follow-up phone call (Visit 6). The total', 'duration of subject participation in the study will be approximately 29 to 31 weeks', 'consisting of 2 weeks pre-screening if necessary, 4 weeks run-in, 24 week treatment and', 'one week Follow-Up.', 'Subjects will be considered to have completed the study upon completion of the Follow-', 'Up contact by telephone.', 'Treatment Arms and Duration', 'Subjects will be stratified based on long-acting bronchodilator usage during the run-in', '(none, one or 2 long-acting bronchodilators per day) and randomized in a ratio of 1:1:1 to', 'either', 'UMEC/VI inhalation powder (62.5/25 mcg once daily) administered via the', 'ELLIPTA DPI) or', 'UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI or', 'Salmeterol (50 mcg BID) administered via DISKUS', '13']\n\n###\n\n", "completion": "END"}